As genetic and biomarker tests become more common, so do new therapies that target specific tumor types and may lead to ...

For the adolescents at baseline, 54.9% of girls and 60.4% of boys were under the 50th percentile for height, while 73.2% and ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

The pharma giant has received the CDSCO nod to import sodium zirconium cyclosilicate powder for oral suspension (Lokelma) in ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong ...

With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

Today we will run through one way of estimating the intrinsic value of AstraZeneca PLC (LON:AZN) by projecting its future ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...